@article{3b65a52c42b644689bccd9d62c8cebbc,
title = "Control of Innate Immune Activation by Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses",
abstract = "The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a public health crisis of unprecedented proportions. After the emergence of SARS-CoV-1 in 2002, and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, this is the third outbreak of a highly pathogenic zoonotic coronavirus (CoV) that the world has witnessed in the last 2 decades. Infection with highly pathogenic human CoVs often results in a severe respiratory disease characterized by a delayed and blunted interferon (IFN) response, accompanied by an excessive production of proinflammatory cytokines. This indicates that CoVs developed effective mechanisms to overcome the host innate immune response and promote viral replication and pathogenesis. In this review, we describe the key innate immune signaling pathways that are activated during infection with SARS-CoV-2 and other well studied pathogenic CoVs. In addition, we summarize the main strategies that these viruses employ to modulate the host immune responses through the antagonism of IFN induction and effector pathways.",
keywords = "SARS-CoV-2, coronavirus, immune evasion, innate immunity, interferon",
author = "Thomas Kehrer and Adolfo Garci{\'a}-Sastre and Lisa Miorin",
note = "Funding Information: Research on CoV in the A.G.-S. laboratory is partly funded by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a National Institute of Al- Funding Information: The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esper-ovax, Farmak and Pfizer. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections, owned by the Icahn School of Medicine at Mount Sinai, New York. Funding Information: lergy and Infectious Diseases (NIAID) supported Center of Excellence for Influenza Research and Response (contracts 75N93019R00028 and HHSN272201400008C); by supplements to NIAID grants R35HL135834, U19AI135972, and U19AI142733 and NIAID contract 75N93019C00045; by a National Cancer Institute (NCI) grant U54CA260560; by a supplement to DoD grant W81XWH-20-1-0270; by the Defense Advanced Research Projects Agency (DARPA) grant HR0011-19-20020; by a Fast/Mercatus grant and by the generous support of the JPB Foundation, the Open Philanthropy Project [research grant 2020–215611 (5384)] and anonymous donors to A.G.-S. Publisher Copyright: {\textcopyright} 2021 Mary Ann Liebert, Inc., publishers.",
year = "2021",
month = jun,
doi = "10.1089/jir.2021.0060",
language = "English",
volume = "41",
pages = "205--219",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "6",
}